Ellagic Acid for Health & Longevity - Quick Reference Sheet

Ellagic Acid for Health & Longevity

Created on 07/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

An inexpensive plant compound from pomegranates, walnuts, and berries, valued mainly for lowering oxidative stress and inflammation — its best-supported effect. Improvements in blood fats and body fat are modest; blood-sugar and longevity claims stay unproven in people. It is poorly absorbed, and benefit hinges on gut bacteria, so results vary widely. (Full Review)

Protocol

Dose
100–500 mg daily
Purified ellagic acid, or 250–1,000 mg standardized pomegranate extract
Timing
With a meal
Improves tolerability and aids gut microbial conversion
Frequency
Once or twice daily
Split dosing maintains gut substrate; once-daily also common
Time to effect
Biomarkers
Weeks to months
Oxidative-stress and lipid markers
Muscle & mitochondria
1–4 months
Via the urolithin A pathway
Trial period
8–12 weeks
Reassess biomarkers; continue only if benefit appears

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Hormone-sensitive cancers
  • Bleeding disorders or anticoagulation
  • Diagnosed iron-deficiency anemia
  • Within ~2 weeks of scheduled surgery
Key Interactions
  • Anticoagulants/antiplatelets (warfarin, clopidogrel, apixaban, aspirin)
  • NSAIDs (ibuprofen, naproxen)
  • CYP3A4-metabolized drugs (statins, amlodipine, midazolam)
  • Iron supplements
  • Antiplatelet/anticoagulant supplements (fish oil, ginkgo, garlic, vitamin E)
  • Blood-sugar–lowering supplements (berberine, cinnamon, alpha-lipoic acid)
  • Direct urolithin A supplements

Risk & Side Effects

  • High: Gastrointestinal discomfort
  • Medium: Reduced non-heme iron and mineral absorption; drug-metabolism interactions
  • Low: Estrogenic hormonal modulation
  • Speculative: Pro-oxidant effects at high doses; antiplatelet and bleeding potential

Monitoring

Marker Target Why
hs-CRP < 1.0 mg/L Tracks the anti-inflammatory effect, ellagic acid's most consistent action
Fasting triglycerides < 80 mg/dL Captures the lipid benefit most likely to respond
HDL-C > 55 mg/dL (men), > 60 mg/dL (women) Monitors the "good" cholesterol shown to rise in human data
Fasting glucose 75–90 mg/dL Screens for any glycemic effect and metabolic status
HbA1c < 5.4% Detects longer-term glycemic change
Ferritin 30–150 ng/mL (higher end for men) Guards against the tannin-related iron-absorption risk
ALT < 25 U/L (men), < 20 U/L (women) Monitors the potential liver-fat benefit and general safety

Cadence: Baseline before first dose, then reassess at ~8–12 weeks, then every 6–12 months; iron status every 6–12 months if at risk of deficiency

Qualitative Assessment

  • Energy levels and exercise tolerance or endurance
  • Muscle strength and recovery after activity
  • Digestive comfort (to detect gastrointestinal side effects)
  • General sense of well-being and cognitive clarity